Clinical Trials Logo

Clinical Trial Summary

This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05199688
Study type Interventional
Source Hoffmann-La Roche
Contact Reference Study ID Number: WN41733
Phone 888-662-6728 (U.S.)
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date May 26, 2022
Completion date February 28, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT03002038 - Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Phase 2/Phase 3
Not yet recruiting NCT04064944 - Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders Phase 2
Completed NCT01845584 - Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Phase 2
Active, not recruiting NCT04660539 - A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3
Completed NCT01777412 - Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Phase 1
Recruiting NCT01623076 - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
Completed NCT01500681 - Maintenance Plasma Exchange for Neuromyelitis Optica
Not yet recruiting NCT05346354 - Phase 2/3 Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Phase 2/Phase 3
Completed NCT02003144 - An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Phase 3
Completed NCT02276963 - Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Phase 1
Recruiting NCT04155424 - A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Phase 2/Phase 3
Completed NCT03819413 - Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital
Completed NCT02893111 - Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Phase 2
Active, not recruiting NCT04201262 - An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD Phase 3
Withdrawn NCT03605238 - Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 Phase 1
Recruiting NCT03900221 - French Registry for Monitoring Pregnancies for Multiple Sclerosis
Completed NCT03138421 - Central Pain Study for ABX-1431 Phase 1
Not yet recruiting NCT05269667 - A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention Phase 4
Enrolling by invitation NCT04886492 - CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)